May 2003
Volume 44, Issue 13
ARVO Annual Meeting Abstract  |   May 2003
A Review of Retinoid Toxicity
Author Affiliations & Notes
  • M. Woodcock
    Ophthalmology, Birmingham and Midland Eye Centre, Birmingham, United Kingdom
  • P. Good
    Ophthalmology, Birmingham and Midland Eye Centre, Birmingham, United Kingdom
  • R.A. Scott
    Ophthalmology, Birmingham and Midland Eye Centre, Birmingham, United Kingdom
  • Footnotes
    Commercial Relationships  M. Woodcock, None; P. Good, None; R.A.H. Scott, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 542. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Woodcock, P. Good, R.A. Scott; A Review of Retinoid Toxicity . Invest. Ophthalmol. Vis. Sci. 2003;44(13):542.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: There are many reports of retinal and optic nerve toxicity caused by the use of retinoids. Documented side effects reported include night blindness, reduced colour vision and reduced visual acuity. As a result the British Civil Aviation Authority (CAA) and the European Joint Aviation Authorities (JAA) bar potential pilots who have taken isotretinoin (Accutane) from holding commercial pilots licences, whilst the U.S. Federal Aviation Administration requires them to undergo basic screening tests. In this study we assessed 42 young adults about to undergo military aircrew training who had a history of retinoid use with a view to evaluating the incidence of ocular toxicity. Methods: Forty two individuals (40 males, 2 females) (age range 19-28) with a history of retinoid use, underwent ocular electrophysiology (VEP, EOG, standard ERG), colour vision analysis, and Goldmann Weekers dark adaptation (DA) testing. These were compared to laboratory normals and 20 age/sex matched normal controls. Results: Forty-one of the patients having taken isotretinoin showed no abnormality in EOG, ERG, VEP, DA or colour vision. The groups mean scotopic ERG b wave amplitude was 423uV (S.D. 23) compared with 408uV (S.D. 49) amongst the controls. The group mean a to b ratio was 0.67 (S.D. 0.04) compared to 0.69 (S.D. 0.06) in the controls. Group mean DA final threshold was 10 1.8 compared to 10 2.1 in controls. One patient who had taken isoretinoin (Etretinate) had an abnormal ERG, impaired dark adaptation and reduced colour vision. Conclusions: These findings show that in 41 young individuals that had taken isotreinoin there was no evidence of retinal or optic nerve toxicity, or impaired dark adaptation. However one case did demonstrate that previous use of isoretinoin may cause permanent retinal toxicity and night blindness. This has important implications for applicants to be commercial or military pilots.

Keywords: drug toxicity/drug effects • electrophysiology: clinical • dark/light adaptation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.